Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612598 | 0.86 | TDP1 (0.34) | TDP1ALDH1A1GAANPSR1 | |
| Gabapentin Enacarbil SCHEMBL977603 | 0.82 | ALDH1A1 (0.41) | ALDH1A1GAA | |
| Gabapentin Enacarbil SCHEMBL25455 | 0.82 | ALDH1A1 (0.41) | ALDH1A1GAA | |
| SCHEMBL12152103 | 0.82 | SLC18A2 (0.30) | — | |
| SCHEMBL13539034 | 0.81 | EPHX2 (0.32) | — | |
| Gabapentin Enacarbil SCHEMBL1077726 | 0.80 | — | — | |
| SCHEMBL15984575 | 0.79 | CTSK (0.33) | — | |
| SCHEMBL1078249 | 0.78 | CTSS (0.42) | ALDH1A1 | |
| SCHEMBL26585 | 0.76 | SLC18A2 (0.31) | — | |
| SCHEMBL7825503 | 0.75 | ALDH1A1 (0.38) | TDP1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283376-A1 | Crystalline Form of y-Aminobutyric Acid Analog | ARBOR PHARMACEUTICALS, LLC | 2020-09-10 | — | — | US | disclosed |
| US-20190152900-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | ARBOR PHARMACEUTICALS LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170183296-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | ARBOR PHARMACEUTICALS, LLC | 2017-06-29 | — | — | US | disclosed |
| US-20150353483-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | XENOPORT, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9150503-B2 | Crystalline form of γ-aminobutyric acid analog | XENOPORT, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140235710-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | XENOPORT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2275401-B1 | Crystalline 1-{[(alpha-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid | XENOPORT INC (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120041061-A1 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES | XENOPORT INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110313036-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | XENOPORT, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-8026279-B2 | Crystalline form of γ-aminobutyric acid analog | XENOPORT, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100056632-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | XENOPORT, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7423169-B2 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080188562-A1 | 1-{[ alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid and 3-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-5-methyl hexanoic acid; extended oral release dosage form with a reduced rate of systemic clearance and without significant side effects | XENOPORT, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080161393-A1 | Use of prodrugs of GABA analogs for treating disease | XENOPORT, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080058546-A1 | Methods for Synthesis of Acyloxyalkyl Derivatives of GABA Analogs | XENOPORT, INC | 2008-03-06 | — | — | US | disclosed |
| US-7232924-B2 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20070049627-A1 | Treating vulvodynia using prodrugs of GABA analogs | XENOPORT, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20050154057-A1 | Crystalline 1-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid; may be used as therapeutic agents in the treatment of neuropathic pain and post-herpetic neuralgia | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2005-07-14 | — | — | US | disclosed |
| US-20040014940-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152900-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | GABRB2, GABRB1, GABRB3 | TDP1 1479/4885ALDH1A1 1810/4885GAA 194/4885 |
| US-20080188562-A1 | 1-{[ alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid and 3-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-5-methyl hexanoic acid; extended oral release dosage form with a reduced rate of systemic clearance and without significant side effects | GABRB1, GABBR1, GABRB2 | TDP1 1621/4885ALDH1A1 148/4885GAA 1451/4885 |
| US-20040014940-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | GABRB1, GABRB3, GABBR1 | TDP1 3201/4885ALDH1A1 495/4885GAA 1099/4885 |
| US-20140235710-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | GABRB2, GABRB1, GABRB3 | TDP1 1479/4885ALDH1A1 1810/4885GAA 194/4885 |
| US-20110313036-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | GABRB2, GABRB1, GABRB3 | TDP1 1479/4885ALDH1A1 1810/4885GAA 194/4885 |
| US-20120041061-A1 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES | GABRB1, GABBR1, GABRB3 | TDP1 1971/4885ALDH1A1 2545/4885GAA 194/4885 |
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | GABRB1, GABRB3, GABBR1 | TDP1 3201/4885ALDH1A1 495/4885GAA 1099/4885 |
| US-20080161393-A1 | Use of prodrugs of GABA analogs for treating disease | GABRB1, GABBR1, GABRB3 | TDP1 1964/4885ALDH1A1 2510/4885GAA 195/4885 |
| US-20150353483-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | GABRB2, GABRB1, GABRB3 | TDP1 1479/4885ALDH1A1 1810/4885GAA 194/4885 |
| US-20080058546-A1 | Methods for Synthesis of Acyloxyalkyl Derivatives of GABA Analogs | GABRB1, GABRB3, GABBR1 | TDP1 3201/4885ALDH1A1 495/4885GAA 1099/4885 |
| US-20050154057-A1 | Crystalline 1-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid; may be used as therapeutic agents in the treatment of neuropathic pain and post-herpetic neuralgia | GABRB1, GABRP, GABRA1 | TDP1 1773/4885ALDH1A1 798/4885GAA 236/4885 |
| US-20200283376-A1 | Crystalline Form of y-Aminobutyric Acid Analog | GABRB2, GABRB1, GABRB3 | TDP1 1479/4885ALDH1A1 1810/4885GAA 194/4885 |
| US-20070049627-A1 | Treating vulvodynia using prodrugs of GABA analogs | GABBR1, GABBR2, GABRB3 | TDP1 674/4885ALDH1A1 445/4885GAA 710/4885 |
| US-20100056632-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | GABRB2, GABRB1, GABRB3 | TDP1 1479/4885ALDH1A1 1810/4885GAA 194/4885 |
| US-20170183296-A1 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG | GABRB2, GABRB1, GABRB3 | TDP1 1479/4885ALDH1A1 1810/4885GAA 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.